Zynerba hopes to crack fragile X at last
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
Becton Dickinson out for blood with new partnership
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Avatera Medical becomes the newest robotic surgery group in Europe
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
